Clinical Trials Logo

Cytokine Release Syndrome clinical trials

View clinical trials related to Cytokine Release Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04150913 Active, not recruiting - Clinical trials for Non Hodgkin Lymphoma

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Start date: October 5, 2020
Phase: Phase 2
Study type: Interventional

This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL). - Relapsed NHL is the condition of returned Non-Hodgkin lymphoma. - Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma. - Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash. - Neurologic toxicity is nervous system disorder characterized by confusion This research study involves two drugs: - Anakinra - Axicabtagene Ciloleucel.

NCT ID: NCT03755414 Active, not recruiting - Clinical trials for Myelodysplastic Syndromes

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Start date: September 4, 2019
Phase: Phase 1
Study type: Interventional

In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT) may mitigate graft-versus-host-disease (GVHD) and cytokine release syndrome (CRS) while retaining Graft-versus-Leukemia (GVL) and improving engraftment. The purpose of this pilot study is to determine the safety of itacitinib with haplo-hematopoietic cell transplantation (HCT) measured by the effect on engraftment and grade III-IV GVHD.